AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JAN 7 - (NewsRx.com & NewsRx.net) -- Following a regularly scheduled meeting of the board of directors, Lipid Sciences, Inc., (LIPD) announced the company will now expand the development program for its HDL Therapy platform.
This decision comes as a result of the board of directors' review of the company's strategic plan, results of Lipid Sciences' development program, recently published data on the promise of HDL Therapy, and the board's approval of the 2004 operating plan and budget.
The company plans to develop the HDL Therapy platform along a parallel path with its Viral Immunotherapy platform. The HDL Therapy platform is aimed at developing potential treatments for the reversal of atherosclerosis. This technology is based on a patented process that selectively and rapidly removes lipids from lipoproteins, such as HDL, without harming the proteins that carry the lipid particles. This HDL Therapy has the ability to boost HDL efficiency and the potential to reduce the risk of cardiovascular disease.
The Viral Immunotherapy platform is focused on the removal of lipid coatings from viruses and other lipid-containing infectious agents. The company recently announced an important development milestone for this viral platform with the completion of successful studies in a mouse animal model. The company has now initiated a series of nonhuman primate studies to further validate its unique delipidation technology. The ultimate goal of these studies is the ...